The proteasome and proteasome inhibitors in multiple myeloma
The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–201 of 201
Gu, J. J., Hernandez‐Ilizaliturri, F. J., Mavis, C. K., Czuczman, N. M., Deeb, G., Gibbs, J. F., Skitzki, J. J., Patil, R., & Czuczman, M. S. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000008 · Cited by 10
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Fricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
Blandino, G., & Di Agostino, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0705-7 · Cited by 201
“Proteasome inhibitors such as bortezomib and carfilzomib are FDA- clinically approved drugs for the treatment of multiple myeloma [101].”
BackgroundBNIP3L/NIX degradation leads to mitophagy deficiency in ischemic brains
Wu, X., Zheng, Y., Liu, M., Li, Y., Ma, S., Tang, W., Yan, W., Cao, M., Zheng, W., Jiang, L., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1802089 · Cited by 196
“Some proteasome inhibitors are used in multiple myeloma therapy [41].”
Background
Metadata
- Authors
- Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G.
- Venue
- Cancer and Metastasis Reviews
- Published
- 2017-12
- Volume
- 36
- Issue
- 4
- Pages
- 561-584
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- OpenAlex
- W2773382289
- Cited by
- 340
- References
- 201
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.